与其他抗生素相比，WIN 49375对癌症患者分离菌株的体外活性。
In vitro activity of WIN 49375 compared with those of other antibiotics in isolates from cancer patients.
作者信息
Garcia I, Bodey G P, Fainstein V, Ho D H, LeBlanc B
出版信息
Antimicrob Agents Chemother. 1984 Sep;26(3):421-3. doi: 10.1128/AAC.26.3.421.
The activity of WIN 49375 [6-fluoro-1, 4-dihydro-1-(methylamino)-7-(4-methyl-1-piperazinyl)-4-oxo-3- quinolinecarboxylic acid], a new synthetic quinolone, was tested in vitro against 587 clinical isolates. The MICs for 90% of isolates of Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae were 0.20, 1.56, and 0.39 microgram/ml, respectively. The MICs for 90% of isolates of Pseudomonas aeruginosa and Serratia marcescens were both 3.12 micrograms/ml. WIN 49375 was minimally active against gram-positive cocci. Its in vitro activity suggests that it may be useful for the treatment of gram-negative bacillary infections.
新型合成喹诺酮WIN 49375 [6-氟-1,4-二氢-1-(甲氨基)-7-(4-甲基-1-哌嗪基)-4-氧代-3-喹啉羧酸] 的活性在体外针对587株临床分离菌进行了测试。大肠杆菌、肺炎克雷伯菌和阴沟肠杆菌90% 分离株的最低抑菌浓度（MIC）分别为0.20、1.56和0.39微克/毫升。铜绿假单胞菌和粘质沙雷氏菌90% 分离株的MIC均为3.12微克/毫升。WIN 49375对革兰氏阳性球菌的活性最低。其体外活性表明它可能对治疗革兰氏阴性杆菌感染有用。
Zotero 插件